Chronic gastritis is a common condition that occurs when an inflammatory infiltrate is present in the gastric mucosa. Diverse factors can cause such inflammation to develop, including food, common bacteria (particularly Helicobacter pylori) and even some viruses. Although the inflammatory infiltrate itself may not cause a disease per se, in some cases gastritis will evolve into atrophic gastritis, ulcers or gastric cancer. Clinicians therefore need to be aware of when gastritis is a harmless condition that can be left alone and when further action is required. In addition, many patients and some clinicians use the term ‘chronic gastritis’ to describe symptoms, mostly those of dyspepsia. This misuse of the terminology can lead to the erroneous conclusion that a diagnosis is being discussed and not a symptom. Here we address these mistakes and some of the others that are frequently made when managing patients with chronic gastritis. We discuss how to avoid making the mistakes to ensure that patients are managed adequately while reducing over treatment.

Abdominal distension and bloating are among the most frequently misunderstood complaints in gastroenterology. They are often used as interchangeable terms, a conceptual mistake that continues to drive diagnostic errors and ineffective treatment. According to Rome IV, bloating and distension may represent either a primary disorder of gut–brain interaction (DGBI) or occur as symptoms with other DGBIs, such as irritable bowel syndrome (IBS), functional dyspepsia (FD) or functional constipation (FC).

Hepatitis C virus (HCV) infection remains an important global health concern. It is estimated that there are approximately 50 million people infected with HCV globally, with around 1 million new infections each year and about 242,000 deaths annually attributed to HCV-related complications. Most acute HCV infections (55–85%) become chronic due to the virus’s effective evasion strategies, with spontaneous clearance being rare once chronicity is established. This condition often progresses silently, with many individuals unaware of their infection until advanced liver damage has occurred. If left untreated, HCV can lead to severe complications, including liver cirrhosis and hepatocellular carcinoma (HCC). HCV transmission occurs mainly through percutaneous exposure to infected blood. HCV can also spread from mother to infant (vertical transmission) and, less frequently, via sexual contact.1,2 In recent years, the introduction of oral direct-acting antivirals (DAAs), with remarkable safety and effectiveness profiles, has led to a sustained virological response (SVR) in virtually all (>97%) HCV-infected patients, regardless of HCV genotype or disease stage. However, significant barriers remain, such as issues with diagnosis, access to treatment and awareness of the disease.

Here, we discuss some of the misconceptions in HCV management and provide a practical management approach grounded in evidence and clinical experience.